Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000008390
JPRN-UMIN000008390
Completed
未知

Paclitaxel plus carboplatin for advanced or recurrent carcinosarcoma of the uterus in Japan. - TC combination chemotherapy for advanced or recurrent carcinosarcoma.

Gynecology, Tohoku University Hospital0 sites35 target enrollmentJuly 9, 2012
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsadvanced or recurrent carcinosarcoma

Overview

Phase
未知
Intervention
Not specified
Conditions
advanced or recurrent carcinosarcoma
Sponsor
Gynecology, Tohoku University Hospital
Enrollment
35
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 9, 2012
End Date
July 1, 2012
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Gynecology, Tohoku University Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •Patients with prior cytotoxic chemotherapy were ineligible. Patients with a history of another invasive malignancy within the previous five years other than a non\-melanoma skin cancer were excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 2
Concurrent paclitaxel and carboplatin-based chemoradiotherapy for stage III or IVA cervical cancer with renal dysfunctio
JPRN-jRCTs031180165Imai Yuichi32
Recruiting
Phase 2
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.recurrent or advanced non-squamous non-small-cell and lung cancer.
JPRN-UMIN000005328Dept. of Respiratory Medicine, Osaka University Hospital45
Completed
Phase 2
Carboplatin and nab-Paclitaxel as first-line treatment in patients with advanced non-small cell lung cancer with interstitial lung disease (HOT1302)on-small cell lung cancer
JPRN-UMIN000012901Hokkaido Lung Cancer Clinical Study Group36
Completed
Phase 1
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II)NSCLCSolid Tumors
NCT01100931National Cancer Institute (NCI)42
Completed
Phase 2
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&ampiumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancer
JPRN-UMIN000006809Akita University Graduate School of Medicine31